---
title: "Pre-market guidance, FDA-aligned principles. · AI SaMD…"
description: "Health Canada's pre-market guidance for machine-learning-enabled medical devices co-evolved with the FDA's. The result: a regulator whose expectations are…"
lang: en
json-ld: |
  [
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "WebSite",
          "@id": "https://ai-samd.com/#website",
          "url": "https://ai-samd.com/",
          "name": "AI SaMD Playbook",
          "description": "Working reference for regulating AI/ML Software as a Medical Device: FDA, EU AI Act, MHRA, Health Canada and NMPA guidance, model risks, and cybersecurity for RA/QA teams.",
          "inLanguage": "en"
        },
        {
          "@type": "Organization",
          "name": "Blue Goat Cyber",
          "url": "https://bluegoatcyber.com"
        }
      ]
    },
    [
      {
        "@context": "https://schema.org",
        "@type": "BreadcrumbList",
        "itemListElement": [
          {
            "@type": "ListItem",
            "position": 1,
            "name": "Home",
            "item": "https://ai-samd.lovable.app/"
          },
          {
            "@type": "ListItem",
            "position": 2,
            "name": "Crosswalk",
            "item": "https://ai-samd.lovable.app/crosswalk"
          },
          {
            "@type": "ListItem",
            "position": 3,
            "name": "Pre-market guidance, FDA-aligned principles.",
            "item": "https://ai-samd.lovable.app/regulators/health-canada"
          }
        ]
      },
      {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "Pre-market guidance, FDA-aligned principles.",
        "description": "Health Canada's pre-market guidance for machine-learning-enabled medical devices co-evolved with the FDA's. The result: a regulator whose expectations are familiar to anyone who has filed with the FDA, with sharper edges around predetermined changes and real-world performance.",
        "about": "Canada · Health Canada",
        "mainEntityOfPage": "https://ai-samd.lovable.app/regulators/health-canada",
        "publisher": {
          "@type": "Organization",
          "name": "Blue Goat Cyber",
          "url": "https://bluegoatcyber.com"
        }
      }
    ]
  ]
---

[AI SaMD Playbook ](/)

Sections[Crosswalk](/#crosswalk)Tools

Search Ctrl K[Talk to us →](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session)

[← Back to crosswalk](/#crosswalk)

HC

Canada · Health Canada

# Pre-market guidance, FDA-aligned principles.

Health Canada's pre-market guidance for machine-learning-enabled medical devices co-evolved with the FDA's. The result: a regulator whose expectations are familiar to anyone who has filed with the FDA, with sharper edges around predetermined changes and real-world performance.

Posture · Advanced · aligned with FDA & MHRA, lifecycle-aware Last reviewed · April 2026 

Key facts

ML-MD pre-market guidance

Apr 2026 (final)

Primary licence

Class II–IV MDL

GMLP principles

Co-author

PCCP-style framework

Yes

§01

## Pre-market expectations for ML-enabled devices

The guidance walks manufacturers through risk-based scoping, data quality, model development, validation, transparency, and post-market monitoring · with explicit hooks for adaptive vs. locked models. The framing is GMLP-first, with regulatory specifics layered on top.

-   Clear articulation of intended use, deployment environment, and user. 
-   Documented data lineage, quality, and bias mitigation. 
-   Validation against representative populations with subgroup analysis. 
-   Defined performance monitoring with thresholds and escalation paths. 

§02

## Predetermined changes

Like the FDA's PCCP, Health Canada expects manufacturers to declare in advance which model changes are anticipated and how they will be controlled. Anything outside that envelope triggers a licence amendment.

§03

## Cybersecurity for medical devices

Health Canada's cybersecurity guidance aligns with IMDRF principles and FDA expectations: threat modelling, SBOM, secure update, vulnerability disclosure, and lifecycle management. For AI SaMD, the model layer is increasingly part of the conversation.

§04

## Real-world performance

The guidance signals a clear expectation that real-world performance · not just pre-market validation · must be monitored, characterised, and reported. This is where adaptive AI either earns trust or attracts scrutiny.

Key takeaways

1.  01 Reuse your FDA evidence base · most of it lands cleanly with Health Canada. 
2.  02 Declare predetermined changes up front; treat them as a licensing constraint. 
3.  03 Build subgroup performance analysis into validation, not as a follow-up. 
4.  04 Stand up real-world performance reporting before launch · the regulator will ask. 

References

-   [Pre-market guidance for ML-enabled medical devices (final, Apr 2026) ↗](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/pre-market-guidance-machine-learning-enabled-medical-devices.html)
-   [Guiding principles · PCCPs for ML-enabled medical devices ↗](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/good-machine-learning-practice-medical-device-development/predetermined-change-control-plans-machine-learning-enabled-medical-devices.html)
-   [Cybersecurity guidance for medical devices ↗](https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/cybersecurity-medical-devices-guidance.html)

[

← Previous

United Kingdom · MHRA

](/regulators/mhra)[

Next →

China · NMPA

](/regulators/nmpa)

© 2026 AI SaMD Playbook · Sponsored by Blue Goat Cyber

[Crosswalk](/crosswalk)[Colophon](/colophon)

Editorial reference only. Not legal or regulatory advice.